Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc., a Delaware biopharmaceutical company listed on Nasdaq under “PHAT,” filed a Form 8-K relating to events on March 17, 2020. The filing references financial results for the fourth quarter and year ended December 31, 2019, announced in a March 19, 2020 press release.
Financial Results and Liquidity
The filing incorporates Exhibit 99.1, a press release announcing fourth-quarter and full-year 2019 financial results. The provided filing text does not include the press release contents or provide clear values for revenue, net income or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material Changes
- The board appointed Mark Stenhouse as a Class I director, effective March 17, 2020, with an initial term expiring at the 2020 annual meeting of stockholders.
- Mr. Stenhouse was appointed to the audit committee and was determined by the board to satisfy applicable Nasdaq independence requirements.
- In connection with the appointment, Mr. Stenhouse received an option to purchase 20,000 shares of common stock. The option has a 10-year term and vests over three years, subject to continued board service.
Outlook, Risks, and Unusual Items
The filing does not provide guidance, an operating outlook, management commentary, or specific risks and contingencies. It states that the Form 8-K information, including Exhibit 99.1, is furnished rather than filed for purposes of Section 18 of the Exchange Act, except where incorporated by specific reference.
Mr. Stenhouse will receive cash compensation under the company’s non-employee director compensation program and will enter into the company’s standard director indemnification agreement. The filing reports no arrangements or understandings related to his selection and no related-person transactions.
Investor Verification Items
- Obtain and review Exhibit 99.1 for the actual fourth-quarter and full-year 2019 financial results.
- Verify year-over-year changes in operating expenses, net loss, cash usage, cash runway, and any financing activity.
- Review the terms, exercise price, and accounting impact of the 20,000-share director option.
- Assess the board’s expanded audit committee composition and Mr. Stenhouse’s independence.